10 results
By adding Cetuximab to standard treatment, we hope to prolonge progression free survival
The primary objective of this trial is to determine if EMD 1201081 (formerly known as IMO-2055) has anti-tumor activity in subjects by examining its effects on accepted clinical endpoints in combination with cetuximab. • To evaluate progression-free…
EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…
Primary objectives:The primary objectives are to evaluate the feasibility of oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE to shorten the qFME procedure and test whether…
Primary objectives:- Determine the value of fluorescence imaging-guided surgery under ambient light conditions for the identification of hybrid tracer-containing SNs as seen on preoperative imaging.Secondary objectives:- Determine the value (…
The purpose of this Safety Lead In study is to explore if encorafenib and cetuximab in combination with a chemotherapy regimen (either mFOLFOX6 or FOLFIRI) are safe and have beneficial effects on you and your colorectal cancer. This is a small…
The aim of this proof-of-concept study is to investigate the feasibility of SLNB in thyroid carcinoma and optimize 68Ga-tilmanocept PET/CT the imaging protocol.
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in…
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…